PWMS News Search Results

Back to NewsWire Home
Back to
  Back to PeopleWithMS NewsWire 

March 2008 Off the Wire . . .




SF-1019 - another compound to track

A small number of patients in the Secondary Progressive and Chronic stages of Multiple Sclerosis (MS) have benefited (PDF) from being treated with SF1019.

SF-1019 is the platform technology of Argyll Biotechnologies. It was developed from extensive research into Biological Response Modifiers (BRMs) undertaken at: Mississippi State University; St George's, University of London (formerly St George's Hospital Medical School); Ohio University; and Methodist Hospital. Argyll Biotechnologies has transferred to Immunosyn Corporation the world-wide rights to market and distribute SF-1019.

E-Mail the NewsWire e-mail the NewsWire ! ! ! - Handpainted and Customized Canes
 with any news items you discover 

copyright 2003